Skip to main content
Clinical Trials/ISRCTN54960762
ISRCTN54960762CompletedNot Applicable

IMIT-1: Lowering the Incidence of vascular complications with Metformin in patients with Impaired glucose Tolerance and a recent transient ischaemic attack or minor ischaemic stroke: a phase II randomised, controlled trial

Erasmus Medical Centre (The Netherlands)0 sites40 target enrollmentStarted: April 11, 2007Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
40

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Sex
All

Inclusion Criteria

  • 1. Men or women 18 years and over
  • 2. TIA/minor ischaemic stroke (modified Rankin Score three or less) within six months
  • 3. Impaired fasting glucose (fasting glucose level of 5.6 to 6.9 mmol/L) and/or impaired glucose tolerance (two-hour post-load glucose level of 7.8 to 11.0 mmol/L)
  • 4. Informed consent

Exclusion Criteria

  • 1. Known or newly diagnosed diabetes mellitus
  • 2. Contraindication for metformin:
  • 2.1. Renal impairment (serum creatinine greater than 135 micromol/L for men, and greater than 110 micromol/L for women)
  • 2.2. Hepatic disease (liver enzymes increased twice the upper limit of normal)
  • 2.3. A past history of lactic acidosis
  • 2.4. Cardiac failure requiring pharmacological therapy
  • 2.5. Chronic hypoxic lung disease
  • 2.6. Pregnancy
  • 2.7. Breast feeding
  • 3. Severe comorbidity interfering with follow-up

Investigators

Sponsor
Erasmus Medical Centre (The Netherlands)

Similar Trials